3 citations
,
October 1994 in “Journal of Labelled Compounds and Radiopharmaceuticals” Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.
September 2023 in “Journal of the American Academy of Dermatology” Low-dose oral naltrexone may help reduce inflammation in some scarring alopecia patients.
August 2024 in “Bioimpacts” Kopexil is an effective and safe hair growth treatment.
December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
43 citations
,
January 1977 in “Toxicology and Applied Pharmacology” Minoxidil is mostly safe, but high doses can cause electrolyte imbalances and heart issues in dogs.
1 citations
,
September 2021 in “Cureus” The rs1128977 gene variant may affect cholesterol and body measurements.
127 citations
,
July 2002 in “EMBO journal” Normal skin cell renewal doesn't need RAR signaling, but vitamin A-related skin thickening does.
14 citations
,
March 2022 in “Plant Cell & Environment” The protein AtRXR3 limits root hair growth in Arabidopsis, affecting phosphorus uptake.
2 citations
,
January 2009 in “Journal of Drug Delivery Science and Technology” Minoxidil in distearyldimethylammonium chloride vesicles significantly promotes hair growth, while minoxidil in microparticles or poloxamer solutions doesn't.
Newer retinoid drugs are effective for skin conditions but have significant side effects.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
Oral minoxidil may have more cardiovascular risks than topical minoxidil.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
36 citations
,
June 2016 in “Journal of dermatological treatment” The combination therapy significantly improved Riehl’s melanosis in patients without serious side effects.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine” 1 citations
,
June 2021 in “International journal of pharmaceutical compounding” Minoxidil in FOAMIL is stable for at least 180 days at various concentrations.
57 citations
,
February 1975 in “Journal of Clinical Investigation” Minoxidil boosts plasma renin activity, influenced by control plasma renin activity and changes in sympathetic tone.
April 2025 in “JAAD Case Reports” Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
4 citations
,
October 2024 in “American Journal of Clinical Dermatology” Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
9 citations
,
July 2017 in “Journal of medical case reports” Ruxolitinib treatment may cause eyelash growth.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
1 citations
,
March 2022 in “Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy” A new, quick method detects minoxidil using silver nanoparticles.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” 4 citations
,
April 2009 in “Journal of Pain” Finasteride boosts morphine's pain relief and prevents tolerance and withdrawal in rats.
24 citations
,
September 2005 in “Journal of Cellular Biochemistry” Retinoids increase steroid sulfatase activity in leukemia cells through RARα/RXR and involves certain pathways like phosphoinositide 3-kinase and ERK-MAP kinase.
13 citations
,
January 1987 in “Dermatology” Minoxidil sulfate relaxes blood vessels by increasing potassium permeability.
6 citations
,
August 2014 in “Spectroscopy Letters” The analysis shows where minoxidil's atoms are likely to react and describes its electronic transitions and behavior with temperature changes.